• Tue news: Regeneron fails to block Eylea biosimilar. Inside the GLP-1 price war. Novartis inks $1B biobucks deal. UCB/Biogen lupus drug. Lilly Alzheimer’s drug approved in Japan. See more on our front page

Dear Compliance...


<







This company has the absolute worst compliance of any company in the industry. I have seen managers give out journal articles to physicians from their thumb drives and more unethical things than I have seen at any other company.
 












Similar threads

Replies
0
Views
1K
Allergan
anonymous
Replies
1
Views
1K
Replies
20
Views
9K
Replies
3
Views
1K